JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07584135 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma

Interventions

DRUG: Injection JS107&Toripalimab& Oxaliplatin Injection& Capecitabine
DRUG: Sintilimab& Oxaliplatin Injection& Capecitabine

Sponsor

NingBo Junyan Hongshi Biosciences Co., Ltd